Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01608490 · ClinicalTrials.gov registry record · NA
Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study
A NA study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 315
- Enrollment target
NCT01608490: Clinical Trial NA study, sponsored by Boston Scientific Corporation.
NCT01608490 is a NA study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 315 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01608490, a NA study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 315 participants
- Enrollment target
Study Summary
Multicenter, randomized, assessor-blinded controlled study of safety and effectiveness of the PneumRx, Inc. RePneu Lung Volume Reduction Coil (RePneu LVRC) System
Primary Outcome
mean absolute change from baseline at 12 months in the 6 Minute Walk Test comparing test and control groups (median if skewed)
Interventions
- DEVICE RePneu Lung Volume Reduction Coil System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2012-10 |
| Est. Completion | 2019-07-26 |
| Phase | NA |
Why NCT01608490 stopped before completion
NCT01608490 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which RePneu Lung Volume Reduction Coil System is the first listed.
NCT01608490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01608490 about?
NCT01608490 is a clinical study titled "Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study". Multicenter, randomized, assessor-blinded controlled study of safety and effectiveness of the PneumRx, Inc. RePneu Lung Volume Reduction Coil (RePneu LVRC) System
What is the current status of trial NCT01608490?
This trial is currently terminated. It is a NA study. The enrollment target is 315 participants. The study started on 2012-10. Estimated completion is 2019-07-26.
What interventions are being tested in trial NCT01608490?
The interventions under investigation include: RePneu Lung Volume Reduction Coil System (DEVICE).
Who is sponsoring clinical trial NCT01608490?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01608490's enrollment target sits among peer trials
315 323rd of 2000 higher than 1,678 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia